From: Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases
BoM/ nBM (N) | BM (N) | |
---|---|---|
patients | 40 | 40 |
deceased | 14 | 14 |
Taxane (#) | 30 | 38 |
DTX | 9 | 15 |
Paclitaxel | 17 | 14 |
both | 4 | 9 |
mean follow-up (##) | ||
days | 2492.95 | 2545.15 |
years | 6.83 | 6.97 |
age primary diagnosis (##) years | 55.6 | 52.4 |
neoadjuvant therapy (#) | ||
yes | 7 | 4 |
no | 29 | 29 |
u | 4 | 7 |
T (#) | ||
T1 | 9 | 7 |
T2 | 15 | 13 |
T3 | 5 | 7 |
T4 | 6 | 7 |
Tx | 1 | 1 |
Tis | 0 | 1 |
u | 4 | 4 |
N (#) | ||
N0 | 10 | 16 |
N1 | 13 | 11 |
N2 | 5 | 4 |
N3 | 8 | 5 |
u | 4 | 4 |
M (#) | ||
M0 | 17 | 23 |
M1 | 15 | 8 |
Mx | 1 | 1 |
u | 7 | 8 |
grading (#) * | ||
G1 | 4 | 0 |
G2 | 14 | 16 |
G3 | 9 | 17 |
u | 13 | 7 |
ER (#) *** | ||
+ | 33 | 17 |
- | 5 | 19 |
u | 2 | 4 |
PR (#) * | ||
+ | 26 | 15 |
- | 12 | 20 |
u | 2 | 5 |
HER2/neu (#) * | ||
+ | 13 | 12 |
- | 24 | 21 |
u | 3 | 7 |
triple negative (#) * | ||
yes | 3 | 9 |
no | 34 | 27 |
u | 3 | 4 |
intrinsic subtype (#) *** | ||
luminal | 34 | 19 |
basal-like | 3 | 9 |
Erb-B2 overexpression | 0 | 8 |
u | 3 | 4 |